Musculoskeletal Disorders

Consensus Statement Issued on Management of Foot, Ankle Gout

November 15, 2018

Risk for gouty flares increased with use of thiazide diuretics, excessive alcohol intake

Denosumab Promising for TDT-Induced Osteoporosis Treatment

November 13, 2018

The researchers found that compared with the placebo group, the DNM group had a higher percentage increase of L1 to L4 bone mineral density (5.92 ± 5.25% vs 2.92 ± 5.56%; P=.043) and wrist bone mineral density (−0.26 ± 5.31 vs −3.92 ± 8.71%; P=.035).

CDC: About One in Three Adults With Prediabetes Has Arthritis

November 09, 2018

The unadjusted prevalence rates of leisure-time physical inactivity and obesity were 56.5 and 50.1%, respectively, among adults with both arthritis and prediabetes.

CDC: Increases in Yoga, Meditation for Children in 2012-2017

November 09, 2018

The researchers found that from 2012 to 2017, there was an increase in the use of yoga (from 3.1 to 8.4%) and meditation (from 0.6 to 5.4%) during the previous 12 months. In 2017, girls were more likely than boys to have used yoga in the previous 12 months.

Statin-Induced Musculoskeletal AEs and Timing of Concurrent Tx Examined

By November 08, 2018

The data showed MAEs onset was significantly faster with atorvastatin and rosuvastatin compared with simvastatin; a comparison with other statins could not be established due to the small number of cases identified.

Biosimilar Hyrimoz Gains FDA Approval

By November 01, 2018

The FDA's approval was supported by data from analytical, preclinical, and clinical research showing that Hyrimoz matched the reference product's safety, efficacy, and quality.

Clinical Characteristics of Patients With AS Who Discontinue TNFis Explored

By October 30, 2018

To compare the characteristics of patients who discontinued TNFis with those who did not, researchers used the Corrona PsA/SpA Registry to identify patients with AS who were on a TNFi and had ≥2 follow-up visits.

Failure to Meet Optimal Urate Levels Increases Mortality Risk in Gout

October 26, 2018

Patients with gout who did not reach a serum uric acid level below 6 mg/dL had a 2.4-fold increased risk for death.

CVD Risk Reduced in Rheumatoid Arthritis Treated With Methotrexate and bDMARDs

October 26, 2018

A reduction in risk for cardiovascular disease has been reported among patients with rheumatoid arthritis who are receiving concomitant therapy with methotrexate and biologic disease-modifying antirheumatic drugs.

Validating Clinical Risk Score of NSAID Toxicity in Osteoarthritis, RA

October 26, 2018

Among the total study population (N=23,953), 5.8% of participants had a predicted 1-year risk of 4%.

Allopurinol Linked to Reduced Risk for CKD Stage ≥3 in Gout

October 25, 2018

Compared with non-users, allopurinol use ≥300mg/day was correlated with a lower risk for developing chronic kidney disease stage ≥3.

Venus Thromboembolism Risk Assessed With Tofacitinib, TNF Inhibitors

October 24, 2018

Although the incidence rate of venous thromboembolism was numerically higher in patients treated with tofacitinib vs TNF inhibitors, the risk was not statistically significant.

Statins May Decrease C-Reactive Protein Levels in Psoriatic Arthritis

October 24, 2018

Statin therapy was associated lower CRP levels in psoriatic arthritis treated with statins, possibly indicating decreased systemic inflammation.

Biologic DMARD Treatment Linked to Weight Gain in Inflammatory Arthritis

October 23, 2018

Small but significant increases in weight (0.02lb) and BMI (0.006 lbl P<.001 for both) were observed over time. Moreover, a negative association between DAS28 and increased weight (-0.56) as well as BMI (-0.08; P<.001 for both) was reported, implying that an increase in weight was linked to lower disease activity.

RAAS Inhibitors and Fracture Risk, Osteoporosis in Postmenopausal Women

October 23, 2018

RAAS inhibitors do not have a deleterious effect on skeletal health in postmenopausal women.

Abatacept May Reduce Diabetes Risk in Rheumatoid Arthritis

October 23, 2018

The researchers concluded their findings indicate that for patients with RA, abatacept reduced the risk for diabetes and "potentially improved insulin sensitivity and glycemic profile."

Ixekizumab Tops Placebo in Axial Spondyloarthritis

October 23, 2018

The researchers found that compared with placebo, the proportion of IXEQ2W and IXEQ4W patients who achieved ASAS 40% response was significantly greater at week 16 (30.6 and 25.4%, respectively, vs 12.5%), with statistically significant differences seen as early as week 1 of treatment.

Walking Each Day May Cut Risk for TKA Over 5 Years

October 23, 2018

Researchers assessed the effect of replacing time not walking with walking at very-light, light, or moderate-to-vigorous intensities on the risk for TKA over 5 years.

Early Initiation of DMARD Tx Tied to Greater Reduction in RA Activity

October 22, 2018

Initiation of DMARD therapy within 6 months of symptom onset was associated with greater reduction in RA disease activity compared with later initiation.

A-Fib, CV Event Risks Examined in PsA Receiving Ustekinumab vs TNF Inhibitors

October 22, 2018

The primary and secondary outcomes included incident AF or a composite CV event that included myocardial infarction, stroke, and coronary revascularization.

High-Dose Trivalent Inactivated Flu Vaccine May Improve Seroconversion Rate in RA

October 22, 2018

These results suggest that high-dose trivalent inactivated influenza vaccine may improve post-vaccine response in immunocompromised patients, including those with RA.

RA Remission Compared for Tofacitinib Alone vs. Steroid Plus Tofacitinib Tx

October 22, 2018

The results support combination therapy with intra-articular steroid injections and tofacitinib to achieve clinical and radiographic remission in patients with early rapid radiographic progression RA.

Upadacitinib, Adalimumab Examined in Treatment-Resistant RA

October 22, 2018

Upadacitinib resulted in greater improvements in rheumatoid arthritis signs and symptoms compared with placebo and adalimumab.

Clinical Efficacy of Tofacitinib Once-Daily vs Twice-Daily Examined in RA

October 22, 2018

Tofacitinib extended release has comparable clinical efficacy to tofacitinib administered twice daily.

Ustekinumab and Secukinumab Safe, Efficacious for Psoriatic Arthritis

October 22, 2018

Among a new line of biological and targeted synthetic DMARD, ustekinumab and secukinumab have shown favorable safety and efficacy profiles for psoriasis and arthritis, respectively in patients with psoriatic arthritis.

Obesity Negatively Affects Treatment Response to JAK Inhibitors in RA

October 22, 2018

Patients treated with JAK inhibitors for rheumatoid arthritis may be less likely to have low disease activity if they are obese compared with those who are overweight.

Heart Failure Risks Identified With Antirheumatic Meds in RA

October 21, 2018

A diagnosis of cardiovascular disease or presence of related biomarkers, as well as the use of antirheumatic drugs may be associated with a higher risk for heart failure in patients with rheumatoid arthritis.

Aspirin, Anticoagulants Similarly Prevent VTE After TKA

October 19, 2018

The researchers found that VTE events occurred in 1.38% of patients, including 4.79% of those who received no pharmacologic prophylaxis, 1.16% treated with aspirin alone, 1.42% of those treated with anticoagulation alone, and 1.31% prescribed both aspirin and anticoagulation.

Posttransplant Outcomes Assessed in Patients Who Resumed TNFi Therapy

By October 18, 2018

Of the 5256 patients who received a renal transplant in the study window (1/1/1998 - 12/31/2017), 14 met inclusion criteria.

Use of NSAIDs for musculoskeletal pain not linked with adverse outcomes

October 13, 2018

In this retrospective cohort analysis, patients with a history of hypertension, chronic kidney disease, or heart failure presenting to primary care physicians for musculoskeletal complaints were frequently prescribed NSAIDs.